CD82 antibody (C-Term)

Catalog No. ABIN1887018

Product Details anti-CD82 Antibody

Target: CD82

Binding Specificity: C-Term

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CD82 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Purification: Affinity chromatography purified via peptide column

Immunogen: 15 amino acid peptide from near the carboxy terminus of human KAI1.

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Handling Advice: Avoid freezing and thawing repeatly.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term use.Store at -20 °C for long term preservation.

Target Details for CD82

Target: CD82

Alternative Name: KAI1 (CD82 Products)

Synonyms: AA682076 antibody, AL023070 antibody, C33 antibody, IA4 antibody, Kai1 antibody, Tspan27 antibody, 4F9 antibody, GR15 antibody, KAI1 antibody, R2 antibody, SAR2 antibody, ST6 antibody, TSPAN27 antibody, CD82 antigen antibody, CD82 molecule antibody, Cd82 molecule antibody, Cd82 antibody, CD82 antibody

Background: KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene.This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression.The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients.Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen.It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases.At least two isoforms of KAI1 are known to exist.
Synonyms: CD82 antigen, tetraspanin-27, Tspan-27, suppressor of tumorgenicity-6

NCBI Accession: NP_002222

Pathways: p53 Signaling